1 Tube, 1 Week, Comprehensive Molecular Results for Cancer Patients
DNA, RNA, MSI and PD-L1 | Somatic and Hereditary
Your genes, right now.
CIRCULOGENE’s molecular diagnostics process is based on the discovery that as tumor cells multiply, they also die, releasing their DNA into the bloodstream. CIRCULOGENE’s comprehensive tumor DNA sequencing is the only testing available that combines minimal volumes of blood with the most advanced next-generation sequencing (NGS) to monitor tumor-mutant DNA within well-characterized, well-documented, cancer-associated genes.
With just one tube of blood, CIRCULOGENE’s patented technology utilizes NGS to monitor thousands of known tumor mutations across multiple cancer-associated genes, providing the most comprehensive information on current FDA-approved treatment options.
Access
Minimal-volume input with maximal yield. One tube for the full range of DNA, RNA, and MSI immunotherapy testing means access to a patient’s blood is even less invasive.
Enrich
Proprietary, direct-on-specimen enrichment technology locates and captures cell-free DNA, identifying and quantifying any tumor mutations for accurate reporting and monitoring.
Detect
Capable of testing more than 50 genes for approximately 3,000 possible mutations. Multi-mutation monitoring capabilities encompass a broad range of tumor profiles and allow for rapid-turnaround, patient-centered, precision medicine.
The CIRCULOGENE Advantage
CAP NUMBER: 9373166
The College of American Pathologists
CLIA NUMBER: 01D2101075
Clinical Laboratory Improvement Amendments (CLIA)